Market Capitalization

With a new CEO and a key investor conference ahead, Metagenomi bets on its unique metagenomics platform and a hemophilia drug to navigate a tough market.

Industrial packaging giant Greif rewards shareholders, but a closer look at its finances and dual-class stock reveals a company in major transition.

Toymaker JAKKS Pacific launches an ambitious new platform targeting the multi-billion dollar anime, manga, and creator markets. Can it beat the competition?

Verrica Pharmaceuticals heads to a key investor conference with strong YCANTH sales, a promising pipeline for warts and skin cancer, and high expectations.

With its newly approved VIZZ eye drop, LENZ Therapeutics is wooing investors, aiming to capture a slice of the massive, underserved presbyopia market.

Anavex Life Sciences adds AMEOS Group CEO Dr. Axel Paeger to its board, a strategic move signaling a push into European markets for its CNS therapies.

With a key drug in trials and a pipeline nearing the clinic, Foghorn Therapeutics brings in a seasoned financial leader to navigate its path to market.

The biotech firm slashed a major acquisition hurdle in a deal with HealthCare Royalty, signaling strong confidence in its cancer drug ZYNLONTA's future.

China’s pioneering EV charging firm NaaS faces a delisting threat from Nasdaq, battling not just low market value but also negative equity and major losses.

First Horizon's financial and credit chiefs will present at a key conference. We dive into their strategy amid industry headwinds and strong 2025 results.

Malaysian solar firm FGL faces delisting after a reverse stock split, meant to save its listing, backfired and wiped out its public share float.

Amid soaring demand, Cleanroom Film & Bags adds a high-speed production line, reinforcing the supply chains for vital medical and semiconductor industries.

Korean brand Laka brings its gender-neutral philosophy to Sephora, betting that US consumers are ready for beauty without rigid rules or boundaries.

F&G Annuities & Life declared its quarterly dividend, offering a sign of stability even as a recent earnings report and stock drop raise questions.

The chemical giant's dramatic dividend cut ends a 14-year growth streak, raising questions about sector health and long-term investor returns.

Seagate retires $600M in debt for cash and stock. A strategic move to fortify its balance sheet, but what does the share dilution mean for investors?

A federal court ruling against Corcept Therapeutics clears a key legal hurdle for Teva's generic Cushing's syndrome drug, rattling investors.

Facing delisting, the Singaporean tech firm enacts a 1-for-20 reverse split. Is it a lifeline or a sign of deeper financial troubles ahead?

Element Biosciences unveils VITARI, a high-throughput benchtop sequencer promising a $100 whole genome, challenging market giants and democratizing genomics.

As it heads to key conferences, Orchestra BioMed is pitching its novel pacemaker-based hypertension treatment and a unique drug-eluting balloon.